110 Combination therapy using molecular-targeted drugs inhibiting platelet-derived growth factor receptors in the tumor microenvironment of renal cell carcinoma
European Urology Supplements(2016)
Abstract
42 mitogen-activated protein kinase in ACHN cells compared with treatment with either agent alone, while the expression levels of Bcl-2, Bcl-xL and p53 after the combined treatment were significantly upregulated compared with those after treatment with either agent alone. In vivo systemic administration of OGX-011 plus axitinib significantly decreased the ACHN tumour volume compared with control ODN plus axitinib. Although no significant differences in the proportions of cells positive for Ki-67 immunostaining or TUNEL assay between the group treated with OGX-011 and that with control ODN, the inhibition of cell proliferation and induction of apoptosis in ACHN tumors treated with OGX-011 and axitinib were markedly remarkable than those in ACHN tumors treated with control ODN and axitinib. CONCLUSIONS: Combined use with OGX-011 may be useful in enhancing the cytotoxic effect of axitinib on RCC by inducing apoptosis and inactivating major signal transduction pathways.
MoreTranslated text
Key words
renal cell carcinoma,growth factor receptors,tumor microenvironment,molecular-targeted,platelet-derived
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined